Multiple Sclerosis: Immunopathology and Treatment Update
AbstractThe treatment of multiple sclerosis (MS) has changed over the last 20 years. All immunotherapeutic drugs target relapsing remitting MS (RRMS) and it still remains a medical challenge in MS to develop a treatment for progressive forms. The most common injectable disease-modifying therapies in RRMS include β-interferons 1a or 1b and glatiramer acetate. However, one of the major challenges of injectable disease-modifying therapies has been poor treatment adherence with approximately 50% of patients discontinuing the therapy within the first year. Herein, we go back to the basics to understand the immunopathophysiology of MS to gain insights in the development of new improved drug treatments. We present current disease-modifying therapies (interferons, glatiramer acetate, dimethyl fumarate, teriflunomide, fingolimod, mitoxantrone), humanized monoclonal antibodies (natalizumab, ofatumumab, ocrelizumab, alemtuzumab, daclizumab) and emerging immune modulating approaches (stem cells, DNA vaccines, nanoparticles, altered peptide ligands) for the treatment of MS. View Full-Text
Share & Cite This Article
Dargahi, N.; Katsara, M.; Tselios, T.; Androutsou, M.-E.; de Courten, M.; Matsoukas, J.; Apostolopoulos, V. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sci. 2017, 7, 78.
Dargahi N, Katsara M, Tselios T, Androutsou M-E, de Courten M, Matsoukas J, Apostolopoulos V. Multiple Sclerosis: Immunopathology and Treatment Update. Brain Sciences. 2017; 7(7):78.Chicago/Turabian Style
Dargahi, Narges; Katsara, Maria; Tselios, Theodore; Androutsou, Maria-Eleni; de Courten, Maximilian; Matsoukas, John; Apostolopoulos, Vasso. 2017. "Multiple Sclerosis: Immunopathology and Treatment Update." Brain Sci. 7, no. 7: 78.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.